Today’s Short Interest: Agios Pharmaceuticals Incorporated (NASDAQ:AGIO) Just Reported Increased Shorts

November 23, 2016 - By Marie Mckinney   ·   0 Comments

Today's Short Interest: Agios Pharmaceuticals Incorporated (NASDAQ:AGIO) Just Reported Increased Shorts

The stock of Agios Pharmaceuticals Incorporated (NASDAQ:AGIO) registered an increase of 9.63% in short interest. AGIO’s total short interest was 6.07M shares in November as published by FINRA. Its up 9.63% from 5.54 million shares, reported previously. With 463,900 shares average volume, it will take short sellers 13 days to cover their AGIO’s short positions. The short interest to Agios Pharmaceuticals Incorporated’s float is 22.12%. About 290,942 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 13.86% since April 21, 2016 and is uptrending. It has outperformed by 8.53% the S&P500.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.50 billion. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders , which are a subset of orphan genetic metabolic diseases. It currently has negative earnings. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insitutional Activity: The institutional sentiment increased to 1.72 in Q2 2016. Its up 0.33, from 1.39 in 2016Q1. The ratio increased, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Tocqueville Asset Management Lp has 13,600 shares for 0.01% of their US portfolio. Price T Rowe Assoc Inc Md holds 0.01% or 831,949 shares in its portfolio. Grp One Trading Limited Partnership last reported 0.01% of its portfolio in the stock. State Board Of Administration Of Florida Retirement System accumulated 35,008 shares or 0% of the stock. Susquehanna Group Llp holds 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 45,839 shares. The Texas-based University Of Texas Investment Managment has invested 4.87% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Proshare Advsr Ltd Llc last reported 29,110 shares in the company. Fmr Limited holds 5.68 million shares or 0.03% of its portfolio. Limited Ca accumulated 0.79% or 260,600 shares. Rhumbline Advisers holds 28,815 shares or 0% of its portfolio. Moreover, Creative Planning has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 8,179 shares. Moreover, Swiss Retail Bank has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 47,560 shares. Teachers Advisors accumulated 23,186 shares or 0% of the stock. Ray Gerald L Associates Ltd has 34,465 shares for 0.23% of their US portfolio. Architects Incorporated holds 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 1,014 shares.

Insider Transactions: Since May 25, 2016, the stock had 0 insider buys, and 9 selling transactions for $5.18 million net activity. Biller Scott had sold 5,000 shares worth $250,000 on Tuesday, September 20. 2,504 shares were sold by Cantley Lewis Clayton Jr., worth $129,432 on Wednesday, May 25.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 12 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Agios Pharmaceuticals has been the topic of 20 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, July 23 by Northland Capital. As per Monday, December 7, the company rating was downgraded by Leerink Swann. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Neutral” rating by Roth Capital on Monday, November 9. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Outperform” rating given on Wednesday, May 18 by Credit Suisse. As per Monday, June 13, the company rating was upgraded by Canaccord Genuity. The rating was maintained by Roth Capital on Wednesday, August 5 with “Hold”. Janney Capital initiated the shares of AGIO in a report on Wednesday, March 2 with “Neutral” rating. The firm has “Overweight” rating by JP Morgan given on Monday, June 13. Needham initiated the stock with “Buy” rating in Monday, October 24 report.

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com with their article: “Why Agios Pharmaceuticals Inc. Presented Lower Today” published on June 09, 2016, Fool.com published: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” on July 03, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Fool.com and their article: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” published on May 06, 2016 as well as Fool.com‘s news article titled: “The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January” with publication date: February 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>